NCT03952312: Oncotool for Cancer Medications

NCT03952312
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Not Applicable
Drug Category: Other

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients who have not initiated a tyrosine-kinase inhibitor (e.g. tucatinib, neratinib, lapatinib) within the past 18 months
https://ClinicalTrials.gov/show/NCT03952312

Comments are closed.

Up ↑